Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).

Detailed Description
-----------------
The ABPA is responsible for pulmonary exacerbations in chronic bronchial diseases. The treatment of ABPA consists in systemic corticosteroids and anti fungal therapy, which can have severe side effects. The diagnosis is difficult, based on several but non-specific characteristics. One of the radiologic abnormalities on CTscan could be more specific : high attenuation in impacted mucus, but this sign is found in about 30% of cases. Recent articles and investigators experience seem to demonstrate that MRI could provide an interesting tool for ABPA diagnosis, studying the signal of bronchial impactions. The aim of the study is to describe the MRI characteristics of patients with ABPA and compare the results with those obtained by CTscan, and in order to determine if there is a specific signal of impaction in ABPA.

Official Title
-----------------
Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses

Conditions
-----------------
Allergic Bronchopulmonary Aspergilloses

Intervention / Treatment
-----------------
* Device: MRI
* Device: CT scan (standard reference)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: study patients have a diagnosis of ABPA control patients have severe asthma All the patients are ≥ 18 years old, have social security care, signature of consent form Exclusion Criteria: cystic fibrosis other type of aspergilloses contraindication for MRI woman without effective contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ABPA<br>15 patients with ABPA | Device: MRI<br>* It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.<br>Device: CT scan (standard reference)<br>* It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.<br>|
| Active Comparator: Severe asthma<br>12 patients with severe asthma | Device: MRI<br>* It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.<br>Device: CT scan (standard reference)<br>* It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concordance between chest CT scan and MRI for bronchial and pulmonary signs of ABPA (bronchiectases, infiltrates, impactions) | Measured by a kappa test | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrashort echo time magnetic resonance imaging